ENTA Enanta Pharmaceuticals, Inc. Stock Quote

ENTA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.83	Insider Own	5.60%	Shs Outstand	20.07M	Perf Week	2.43%
Market Cap	942.34M	Forward P/E	-	EPS next Y	-5.71	Insider Trans	-0.53%	Shs Float	17.70M	Perf Month	9.11%
Income	-36.20M	PEG	-	EPS next Q	-0.79	Inst Own	95.30%	Short Float	12.92%	Perf Quarter	4.73%
Sales	122.50M	P/S	7.69	EPS this Y	-182.00%	Inst Trans	0.08%	Short Ratio	13.33	Perf Half Y	-12.72%
Book/sh	22.70	P/B	2.06	EPS next Y	-41.00%	ROA	-7.20%	Target Price	61.88	Perf Year	-20.25%
Cash/sh	19.17	P/C	2.44	EPS next 5Y	-	ROE	-7.60%	52W Range	38.40 - 59.63	Perf YTD	10.97%
Dividend	-	P/FCF	165.32	EPS past 5Y	-19.60%	ROI	-9.40%	52W High	-21.65%	Beta	0.42
Dividend %	-	Quick Ratio	18.10	Sales past 5Y	-5.30%	Gross Margin	-	52W Low	21.67%	ATR	1.90
Employees	141	Current Ratio	18.10	Sales Q/Q	-54.00%	Oper. Margin	-34.00%	RSI (14)	58.08	Volatility	5.49% 4.24%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-432.10%	Profit Margin	-29.50%	Rel Volume	0.67	Prev Close	48.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 23 AMC	Payout	-	Avg Volume	171.53K	Price	46.72
Recom	2.60	SMA20	5.99%	SMA50	6.43%	SMA200	-2.55%	Volume	114,485	Change	-3.35%

Nov-24-20

Initiated

Evercore ISI

Underperform

$30

Aug-28-20

Resumed

ROTH Capital

Buy

$104

Aug-26-20

Initiated

Piper Sandler

Overweight

$87

Jul-27-20

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$70

Mar-17-20

Upgrade

Robert W. Baird

Neutral → Outperform

$60

Nov-22-19

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Sep-26-19

Downgrade

JP Morgan

Neutral → Underweight

$86 → $57

May-24-19

Initiated

Wolfe Research

Outperform

$117

Apr-23-19

Upgrade

Berenberg

Hold → Buy

$80 → $120

Dec-13-18

Initiated

Berenberg

Hold

$80

Jun-06-18

Initiated

ROTH Capital

Buy

$133

Feb-08-18

Downgrade

JP Morgan

Overweight → Neutral

Jan-02-18

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Nov-21-17

Reiterated

RBC Capital Mkts

Outperform

$54 → $58

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$54

Jul-11-17

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

Apr-28-16

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Feb-09-16

Reiterated

Barclays

Underweight

$16 → $18

Oct-23-15

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$32

Oct-23-15

Downgrade

Barclays

Equal Weight → Underweight

$45 → $16

Jan-08-21 07:01AM	Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-21 07:01AM	Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology Business Wire
06:00AM	Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-20 10:40PM	Is ENTA A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-08-20 07:01AM	Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development Business Wire
Nov-25-20 12:10AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
Nov-23-20 10:00PM	Enanta Pharmaceuticals Inc (ENTA) Q4 2020 Earnings Call Transcript Motley Fool
05:35PM	Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:19PM	Enanta Pharmaceuticals: Q4 Earnings Insights Benzinga
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Business Wire
02:15PM	Enanta Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-20-20 10:03AM	Earnings Preview: Enanta Pharmaceuticals Benzinga
Nov-18-20 07:02AM	Enanta Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Nov-16-20 07:02AM	Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Business Wire
Nov-12-20 12:30PM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-27-20 09:54AM	New Strong Sell Stocks for October 27th Zacks
Oct-12-20 01:27PM	Is Enanta Pharmaceuticals Inc (ENTA) Going to Burn These Hedge Funds? Insider Monkey
Sep-28-20 07:00AM	Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference Business Wire
Sep-14-20 07:00AM	Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis Business Wire
Sep-03-20 07:01AM	Enanta Pharmaceuticals to Participate in Upcoming September Conferences Business Wire
Aug-28-20 06:15AM	Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress 2020 Business Wire
Aug-26-20 09:42AM	Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga
Aug-20-20 07:00AM	Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress 2020 Business Wire
Aug-07-20 09:28AM	Were Hedge Funds Right About Ditching Enanta Pharmaceuticals Inc (ENTA)? Insider Monkey
Aug-05-20 01:31AM	Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript Motley Fool
Aug-04-20 06:35PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:21PM	Recap: Enanta Pharmaceuticals Q3 Earnings Benzinga
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire
Aug-03-20 07:02AM	Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020 Business Wire
Jul-28-20 12:32PM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
07:01AM	Enanta Pharmaceuticals to Host Conference Call on August 4 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2020 Business Wire
Jul-17-20 01:41PM	Are Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? Simply Wall St.
Jul-09-20 07:01AM	Enanta Pharmaceuticals Announces Clinical Trial Progress for EDP-514, its Lead Core Inhibitor for Hepatitis B Virus Business Wire
Jun-29-20 07:00AM	Enanta Pharmaceuticals Announces the Appointment of Mark G. Foletta to Its Board of Directors Business Wire
Jun-23-20 12:23PM	Hedge Funds Are Selling Enanta Pharmaceuticals Inc (ENTA) Insider Monkey
Jun-11-20 07:02AM	Enanta Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference Business Wire -5.74%
Jun-04-20 10:20PM	Edited Transcript of ENTA earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-23-20 09:58AM	If You Had Bought Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Three Years Ago, You Could Pocket A 84% Gain Today Simply Wall St.
May-14-20 08:53AM	Why Enanta Pharmaceuticals (ENTA) Stock Might be a Great Pick Zacks
May-12-20 07:30AM	Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference Business Wire
May-09-20 09:43PM	Were Hedge Funds Right About Enanta Pharmaceuticals Inc (ENTA)? Insider Monkey
May-07-20 12:01AM	Enanta Pharmaceuticals Inc (ENTA) Q2 2020 Earnings Call Transcript Motley Fool
May-06-20 06:45PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:03PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET Business Wire
04:03PM	Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis Business Wire
Apr-29-20 12:34PM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-28-20 04:05PM	Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2020 Business Wire -7.59%
12:33PM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-17-20 10:19AM	Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Too Much Debt? Simply Wall St.
Mar-26-20 04:05PM	Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic Business Wire +6.63%
Mar-13-20 07:00AM	Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 Business Wire +9.19%
Mar-06-20 07:05AM	Enantas HCV Collaboration Partner AbbVie Receives Marketing Authorization from European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) Duration to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis Business Wire
Mar-04-20 08:09AM	Does Market Volatility Impact Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Share Price? Simply Wall St.
Feb-12-20 12:18AM	Edited Transcript of ENTA earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-06-20 05:15PM	Enanta Pharmaceuticals (ENTA) Q1 Earnings Top Estimates Zacks
04:00PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Business Wire
02:30PM	Enanta Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 04:11PM	13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Feb-03-20 07:27AM	Is Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) High P/E Ratio A Problem For Investors? Simply Wall St.
Jan-30-20 12:31PM	Earnings Preview: Enanta Pharmaceuticals (ENTA) Q1 Earnings Expected to Decline Zacks
Jan-24-20 07:30AM	Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019 Business Wire
Jan-14-20 05:30AM	AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary CNW Group
Jan-09-20 07:30AM	Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-20 08:44AM	Does This Valuation Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Imply Investors Are Overpaying? Simply Wall St.
Dec-30-19 07:30AM	Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-11-19 11:25AM	Is Enanta Pharmaceuticals Inc (ENTA) A Good Stock To Buy? Insider Monkey
Dec-09-19 07:38AM	Should You Worry About Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pay Cheque? Simply Wall St.
Dec-07-19 11:24PM	Edited Transcript of ENTA earnings conference call or presentation 21-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-22-19 08:18AM	The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 05:15PM	Enanta Pharmaceuticals (ENTA) Lags Q4 Earnings and Revenue Estimates Zacks
04:00PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Business Wire
07:22AM	The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-17-19 08:42AM	The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-14-19 10:30AM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Nov-11-19 10:21AM	Is Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) 14% ROE Worse Than Average? Simply Wall St.
07:30AM	Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019 Business Wire
Nov-05-19 04:00PM	Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Business Wire
Oct-27-19 10:29PM	Enanta Pharmaceuticals Inc (ENTA): Hedge Funds In Wait-and-See Mode Insider Monkey
Oct-21-19 04:00PM	Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference Business Wire
Oct-12-19 10:03AM	Is Enanta Pharmaceuticals's (NASDAQ:ENTA) Share Price Gain Of 145% Well Earned? Simply Wall St.
Oct-03-19 07:30AM	New Data from Enantas Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay Business Wire
Sep-30-19 04:48PM	Six Mass. businesses make Fortunes list of 100 fastest-growing companies American City Business Journals
Sep-26-19 04:16PM	This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years Investor's Business Daily -15.11%
11:40AM	Enanta's Stock Down Despite NASH Drug Meeting Goal in Study Zacks
07:54AM	The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J Benzinga
Sep-25-19 04:28PM	UPDATE 1-Enanta Pharma's NASH drug meets mid-stage study goal Reuters
04:12PM	Enanta Pharma's liver disease drug meets mid-stage study goal Reuters
04:00PM	Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH Business Wire
Sep-12-19 09:48AM	Is Enanta Pharmaceuticals (NASDAQ:ENTA) A Risky Investment? Simply Wall St.
Sep-10-19 07:30AM	New Data from Enantas Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek 2019 Business Wire
Aug-21-19 07:30AM	Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference Business Wire
Aug-19-19 02:54PM	Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-19 01:24PM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Aug-07-19 12:37PM	Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 05:55PM	Enanta Pharmaceuticals (ENTA) Q3 Earnings Surpass Estimates Zacks
04:00PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Business Wire
Aug-02-19 08:51AM	Enantas HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis Business Wire
Jul-30-19 10:38AM	Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Jul-15-19 07:30AM	Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Business Wire
Jul-11-19 09:00AM	Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know Zacks

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MELLETT PAUL J	Treasurer and CFO	Jan 08	Sale	45.58	6,000	273,463	61,759	Jan 08 08:57 PM
Gardiner Nathaniel S.	Sr. VP & General Counsel	Dec 03	Option Exercise	30.00	1,667	50,010	38,538	Dec 07 05:38 PM
MELLETT PAUL J	Treasurer and CFO	Nov 11	Option Exercise	2.54	3,480	8,849	46,304	Nov 12 04:12 PM
Gardiner Nathaniel S.	Sr. VP & General Counsel	Aug 05	Option Exercise	30.00	1,666	49,980	29,271	Aug 06 04:38 PM
MELLETT PAUL J	Treasurer and CFO	May 05	Option Exercise	1.21	1,740	2,100	42,824	May 07 05:35 PM
Gardiner Nathaniel S.	Sr. VP & General Counsel	Mar 12	Option Exercise	30.00	3,000	90,000	27,605	Mar 16 06:27 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience